News & Events
News & Events
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
August 25, 2022
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug DevelopmentC-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug development TUCSON, Ariz. and WASHINGTON, DC, August 25, 2022 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) will host its in-person annual workshop on September 13...
April 14, 2022
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium
Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.
Dr. Rakhilin joined C-Path after working in the pharmaceutical industry for 15 years. His work focused on various aspects of drug development, from target identification to clinical studies and biomarker analysis. He has contributed to the development of several treatments for muscle atrophy, hematological, and neurodegenerative diseases.
April 8, 2021
CP-SCD Announces Pfizer Executive as its First Industry Co-DirectorC-Path’s Critical Path to Sickle Cell Disease Consortium (CP-SCD) is pleased to announce Dr. David Readett of Pfizer as its first Industry Co-Director. David is a pediatrician/pediatric hematologist/oncologist who, prior to transitioning to clinical research in the pharmaceutical industry, spent 18 years in clinical practice, with a focus on clinical care and research for pediatric...